JP2022548043A5 - - Google Patents

Info

Publication number
JP2022548043A5
JP2022548043A5 JP2022516107A JP2022516107A JP2022548043A5 JP 2022548043 A5 JP2022548043 A5 JP 2022548043A5 JP 2022516107 A JP2022516107 A JP 2022516107A JP 2022516107 A JP2022516107 A JP 2022516107A JP 2022548043 A5 JP2022548043 A5 JP 2022548043A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022516107A
Other languages
English (en)
Japanese (ja)
Other versions
JP7665600B2 (ja
JP2022548043A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2020/051230 external-priority patent/WO2021046653A1/en
Publication of JP2022548043A publication Critical patent/JP2022548043A/ja
Publication of JP2022548043A5 publication Critical patent/JP2022548043A5/ja
Priority to JP2025064114A priority Critical patent/JP2025118629A/ja
Application granted granted Critical
Publication of JP7665600B2 publication Critical patent/JP7665600B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516107A 2019-09-13 2020-09-11 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 Active JP7665600B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064114A JP2025118629A (ja) 2019-09-13 2025-04-09 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900303P 2019-09-13 2019-09-13
US62/900,303 2019-09-13
PCT/CA2020/051230 WO2021046653A1 (en) 2019-09-13 2020-09-11 Anti-oncolytic virus antigen antibodies and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064114A Division JP2025118629A (ja) 2019-09-13 2025-04-09 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022548043A JP2022548043A (ja) 2022-11-16
JP2022548043A5 true JP2022548043A5 (cg-RX-API-DMAC7.html) 2023-09-15
JP7665600B2 JP7665600B2 (ja) 2025-04-21

Family

ID=74867304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516107A Active JP7665600B2 (ja) 2019-09-13 2020-09-11 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法
JP2025064114A Pending JP2025118629A (ja) 2019-09-13 2025-04-09 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064114A Pending JP2025118629A (ja) 2019-09-13 2025-04-09 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法

Country Status (10)

Country Link
US (1) US20230027475A1 (cg-RX-API-DMAC7.html)
EP (1) EP4028417A4 (cg-RX-API-DMAC7.html)
JP (2) JP7665600B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220093103A (cg-RX-API-DMAC7.html)
CN (2) CN118834291A (cg-RX-API-DMAC7.html)
AU (1) AU2020346632A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022004575A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154214A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002855A (cg-RX-API-DMAC7.html)
WO (1) WO2021046653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4043482A4 (en) * 2019-10-02 2024-03-13 Bionoxx Inc. TUMOR TARGETING PROTEIN OR ASSOCIATED FRAGMENT, ANTIBODIES BINDING THEREWITH AND ITS USE
US20240309070A1 (en) * 2021-03-17 2024-09-19 adMare Therapeutics Society Anti-vaccinia virus antigen antibodies and related compositions and methods
KR102419397B1 (ko) * 2021-04-02 2022-07-14 주식회사 바이오녹스 항암바이러스 유래 단백질을 표적으로 하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도
KR102739298B1 (ko) * 2021-04-02 2024-12-06 주식회사 바이오녹스 바이러스 벡터 유래 항암요법 표적 단백질 및 이에 특이적으로 결합하는 결합 분자 또는 이의 단편
CA3216069A1 (en) * 2021-04-05 2022-10-13 Bionoxx Inc. Viral vector-derived target protein for anticancer therapy and binding molecule or fragment thereof specifically binding thereto
CN117480245A (zh) * 2021-04-05 2024-01-30 拜耳诺克斯有限公司 靶向源自溶瘤病毒的蛋白的嵌合抗原受体、表达其的免疫细胞及两者的用途
KR102759386B1 (ko) * 2022-08-11 2025-01-24 성균관대학교산학협력단 89Zr 표지된 항-CD25 항체를 이용한 immuno-PET
KR102770091B1 (ko) * 2023-04-03 2025-02-24 주식회사 셀랩메드 종양 용해성 바이러스 단백질-특이적 키메릭 항원 수용체 및 이의 용도
WO2024210531A1 (ko) * 2023-04-03 2024-10-10 주식회사 셀랩메드 종양 용해성 바이러스 단백질-특이적 키메릭 항원 수용체 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075914A2 (en) * 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies against orthopoxviruses
JP2010507362A (ja) * 2006-08-23 2010-03-11 ケルセジーン ファーマ リミテッド ライアビリティ カンパニー 天然痘モノクローナル抗体
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
BRPI0822556B1 (pt) * 2008-03-26 2022-03-03 Epitomics, Inc Anticorpo monoclonal anti-vegf e composição farmacêutica
US11155622B2 (en) * 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
EA201891420A1 (ru) * 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
AU2018309735B2 (en) * 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
CN111163803B (zh) * 2017-08-11 2025-05-09 希望之城公司 表达car t细胞靶物的溶瘤病毒及其用途
US20240309070A1 (en) * 2021-03-17 2024-09-19 adMare Therapeutics Society Anti-vaccinia virus antigen antibodies and related compositions and methods

Similar Documents

Publication Publication Date Title
JP7199494B2 (ja) Cd47に対するヒト化及びキメラモノクローナル抗体
US10781256B2 (en) Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies
TWI743461B (zh) 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JP2021528973A5 (cg-RX-API-DMAC7.html)
JP2022523507A5 (cg-RX-API-DMAC7.html)
CN113583116B (zh) 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途
WO2020252907A1 (zh) 抗cd3e和bcma双特异性抗体及其用途
CN106659779A (zh) 双特异性四价抗体及其制造和使用方法
JP2020533004A5 (cg-RX-API-DMAC7.html)
WO2021197359A1 (zh) 一种构建多特异性抗体的平台
JP2023524102A5 (cg-RX-API-DMAC7.html)
CN114786720B (zh) TriAx抗体的组合物及其制备和使用方法
JP2022513050A5 (cg-RX-API-DMAC7.html)
JP2025506341A5 (cg-RX-API-DMAC7.html)
CA3180690A1 (en) Cd38 antibodies for treatment of human diseases
US20230406929A1 (en) Polypeptide constructs binding to cd3
CN120981244A (zh) Vhh抗体和其用途
US20230406887A1 (en) Antigen binding domain with reduced clipping rate
JP2024513700A5 (cg-RX-API-DMAC7.html)
WO2023143273A1 (zh) 新型长效化和高活性且更安全的抗体构建体
JP2023548471A5 (cg-RX-API-DMAC7.html)
CN105229034B (zh) 用于与抗体药物偶联物疗法一起使用的免疫成像剂
JP2023536630A5 (cg-RX-API-DMAC7.html)
JP2022517329A5 (cg-RX-API-DMAC7.html)
JP2025512923A5 (cg-RX-API-DMAC7.html)